DUBLIN--(BUSINESS WIRE)--The "Cytochrome P450 17 (CYP17) Inhibitor -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.
Cytochrome P450 17 (CYP17) Inhibitor - Pipeline Insight, 2018' report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cytochrome P450 17 (CYP17) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Cytochrome P450 17 (CYP17) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. Cytochrome P450 17 (CYP17) Inhibitor - Overview
3. Pipeline Therapeutics4. Comparative Analysis
5. Cytochrome P450 17 (CYP17) Inhibitor Pipeline Products in Clinical Stages
6. Cytochrome P450 17 (CYP17) Inhibitor Pipeline Products in Non-clinical Stages
7. Therapeutic Assessment: Active Products
8. Inactive Pipeline Products
- Churchill Pharmaceuticals
- Asana BioSciences
- Tokai Pharmaceuticals
- Endo Pharmaceuticals
- Beta Pharma
- Solural Pharma
- Viamet Pharmaceuticals
- Janssen Research & Development
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/qzbsb4/cytochrome_p450?w=4